Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274633 | 0.87 | RAB9A (0.76) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| SCHEMBL14768931 | 0.84 | RAB9A (0.72) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| Phenindione SCHEMBL29388073 | 0.81 | MAPT (1.00) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| Phenindione SCHEMBL33831 | 0.81 | MAPT (1.00) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| SCHEMBL10559114 | 0.79 | MAPT (0.95) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| Phenindione SCHEMBL6827577 | 0.79 | MAPT (0.95) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| Phenindione SCHEMBL1443973 | 0.79 | MAPT (0.95) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| SCHEMBL14940174 | 0.78 | MAPT (0.63) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| Phenindione SCHEMBL16782144 | 0.77 | MAPT (0.91) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| SCHEMBL6607855 | 0.76 | MAPT (0.65) | RAB9AMAPTNPC1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10768174-B2 | Attachment of proteins to interfaces for use in nonlinear optical detection | BLUELIGHT THERAPEUTICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200064354-A1 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT ANALYSIS OF CONFORMATION IN BIOLOGICAL ENTITIES | QUANTA THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10451630-B2 | Systems and methods for high throughput analysis of conformation in biological entities | Biodesy, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180340940-A1 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT ANALYSIS OF CONFORMATION IN BIOLOGICAL ENTITIES | QUANTA THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| US-20170350883-A1 | ATTACHMENT OF PROTEINS TO INTERFACES FOR USE IN NONLINEAR OPTICAL DETECTION | QUANTA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| WO-2013068785-A1 | INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
| US-8431717-B2 | Process for the preparation of 5-(2-ethyl-dihydro-1H-inden-2-yl)-1H-imidazole and salts thereof | JSC GRINDEKS (LV) | 2013-04-30 | — | — | US | disclosed |
| EP-2225209-B1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS JSC (LV) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | JSC GRINDEKS (LV) | 2011-02-03 | — | — | US | disclosed |
| EP-2225209-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | Grindeks, a joint stock company (LV) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071584-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028733-A1 | PROCESS FOR THE PREPARATION OF 5-(2-ETHYL-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE AND SALTS THEREOF | CYP3A5, CYP3A4, IPO5 | RAB9A 2556/4885MAPT 1241/4885NPC1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.